In this study, we confirmed that FAK is upregulated in IPF lung tissue and therefore FAK inhibition can be used as a therapeutic strategy against TGF-β1-induced ECM remodeling. The gene discussed is PTK2; the disease is idiopathic interstitial pneumonia.